Advances in Therapy

, Volume 19, Issue 2, pp 61–72 | Cite as

Future directions in lipid therapies

  • Benjamin Ansell


Cholesterol management to reduce the burden of cardiovascular disease is a major public health concern. Despite widespread recognition of lipid abnormalities as cardiovascular risk factors, significant cardiovascular event reductions with cholesterol-lowering therapies, and dissemination of treatment guidelines, most high-risk patients are not at target lipid levels. In addition to lifestyle changes, four major drug classes are available to modify lipid levels: fibrates, niacin, resins, and statins. High efficacy and tolerability in clinical trials make statins the most widely prescribed of these agents. Newer, more potent members of this class and novel formulations of niacin and resins may provide more effective therapy for dyslipidemia with fewer side effects. Several agents in development (cholesterolabsorption inhibitors and ACAT inhibitors) exploit mechanisms of action complementary to those of current treatments and combined with statins may produce greater improvements in lipid profiles than are now possible. These innovations should enable a greater number of patients to achieve more aggressive cholesterol goals, thereby reducing the risk of cardiovascular events.


statin cholesterol atherosclerosis coronary heart disease 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    American Heart Association.2001 Heart and Stroke Statistical Update. Dallas, Tex: American Heart Association; 2000.Google Scholar
  2. 2.
    Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).JAMA.2001;285:2486–2497.CrossRefGoogle Scholar
  3. 3.
    Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyörälä K. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and Other Societies on Coronary Prevention.Eur Heart J. 1998;19:1434–1503.CrossRefGoogle Scholar
  4. 4.
    Maron DJ, Fazio S, MacRae FL. Current perspectives on statins.Circulation. 2000;101:207–213.PubMedGoogle Scholar
  5. 5.
    Pearson TA, Laurora I, Chu H, Kafonek S. The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals.Arch Intern Med. 2000;160: 459–467.PubMedCrossRefGoogle Scholar
  6. 6.
    Shepherd J. Lipoprotein metabolism: an overview.Drugs. 1994;47(suppl 2):1–10.PubMedCrossRefGoogle Scholar
  7. 7.
    Zhang B, Saku K, Ohta T. In vivo metabolism of HDL, apo A-I, and lp A-I, and function of HDL-a clinical perspective.J Atheroscler Thromb. 2000;7:59–66.PubMedGoogle Scholar
  8. 8.
    Temple NJ. Dietary fats and coronary heart disease.Biomed Pharmacother. 1996;50:261–268.PubMedCrossRefGoogle Scholar
  9. 9.
    Brown L, Rosner B, Willett WW, Sacks FM. Cholesterol-lowering effects of dietary fiber: a meta-analysis.Am J Clin Nutr. 1999;69:30–42.PubMedGoogle Scholar
  10. 10.
    MacMahon M, Carless J. Ispaghula husk in the treatment of hypercholesterolaemia: a doubleblind controlled study.J Cardiovasc Risk. 1998;5:167–172.PubMedCrossRefGoogle Scholar
  11. 11.
    Harris WS. Ω-3 Fatty acids and serum lipoproteins: human studies.Am J Clin Nutr. 1997; 65(suppl 5):1645S-1654S.PubMedGoogle Scholar
  12. 12.
    Daviglus ML, Stamler J, Orencia AJ, et al. Fish consumption and the 30-year risk of myocardial infarction.NEngl J Med. 1997;336:1046–1053.CrossRefGoogle Scholar
  13. 13.
    Harris WS, Isley WL. Clinical trial evidence for the cardioprotective effects of omega-3 fatty acids.Curr Atheroscler Rep. 2001;3:174–179.PubMedCrossRefGoogle Scholar
  14. 14.
    GISSI-Prevenzione Investigators. Dietary supplementation with Ω-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial.Lancet. 1999; 354:447–455.CrossRefGoogle Scholar
  15. 15.
    Knopp RH. Drug treatment of lipid disorders.N Engl J Med. 1999;341:498–511.PubMedCrossRefGoogle Scholar
  16. 16.
    Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).Lancet. 1994;344:1383–1389.CrossRefGoogle Scholar
  17. 17.
    Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.N Engl J Med. 1995;333:1301–1307.PubMedCrossRefGoogle Scholar
  18. 18.
    Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.N Engl J Med. 1996;335:1001–1009.PubMedCrossRefGoogle Scholar
  19. 19.
    Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS.JAMA. 1998;279:1615–1622.PubMedCrossRefGoogle Scholar
  20. 20.
    The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.N Engl J Med. 1998;339:1349–1357.CrossRefGoogle Scholar
  21. 21.
    Guay DR. Micronized fenofibrate: a new fibric acid hypolipidemic agent.Ann Pharmacother. 1999;33:1083–1103.PubMedCrossRefGoogle Scholar
  22. 22.
    Durrington P, Tuomilehto J, Hamann A, Southworth H, Pears J, Kallend D. Effects of rosuvastatin alone and in combination with fenofibrate on lipid subfractions in patients with type 2 diabetes: results at 24 weeks.Circulation. 2001;104:II-177.Google Scholar
  23. 23.
    Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results, I: reduction in the incidence of coronary heart disease.JAMA. 1984;251:351–364.CrossRefGoogle Scholar
  24. 24.
    Hiatt JG, Shamsie SG, Schectman G. Discontinuation rates of cholesterol-lowering medications: implications for primary care.Am J Manag Care. 1999;5:437–444.PubMedGoogle Scholar
  25. 25.
    Knopp RH, Ginsberg J, Albers JJ, et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin.Metabolism. 1985;34:642–650.PubMedCrossRefGoogle Scholar
  26. 26.
    Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease.JAMA. 1975;231:360–381.CrossRefGoogle Scholar
  27. 27.
    Brown BG, Zhao X-Q, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.N Engl J Med. 2001;345:1583–1592.PubMedCrossRefGoogle Scholar
  28. 28.
    Knopp RH. Evaluating niacin in its various forms.Am J Cardiol. 2000;86(suppl 1):51L-56L.PubMedCrossRefGoogle Scholar
  29. 29.
    Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus.JAMA. 1990;264:723–726.PubMedCrossRefGoogle Scholar
  30. 30.
    Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral artery disease: the ADMIT study: a randomized trial.JAMA. 2000;284:1263–1270.PubMedCrossRefGoogle Scholar
  31. 31.
    Kesaniemi YA, Miettinen TA. Cholesterol absorption efficiency regulates plasma cholesterol level in the Finnish population.Eur J Clin Invest. 1987;17:391–395.PubMedCrossRefGoogle Scholar
  32. 32.
    Heinemann T, Kullak-Ublick G-A, Pietruk B, von Bergmann K. Mechanisms of action of plant sterols on inhibition of cholesterol absorption.Eur J Clin Pharmacol. 1991;40(suppl 1):S59-S63.PubMedCrossRefGoogle Scholar
  33. 33.
    Neil HA, Meijer GW, Roe LS. Randomised controlled trial of use by hypercholesterolaemic patients of a vegetable oil sterol-enriched fat spread.Atherosclerosis. 2001;156:329–337.PubMedCrossRefGoogle Scholar
  34. 34.
    Best MM, Duncan CH, Van Loon EJ, Wathen JD. Lowering of serum cholesterol by the administration of a plant sterol.Circulation. 1954;10:201–206.PubMedGoogle Scholar
  35. 35.
    Law M. Plant sterol and stanol margarines and health.BMJ. 2000;320:861–864.PubMedCrossRefGoogle Scholar
  36. 36.
    Davis HR, Compton DS, Hoos L, Tetzloff G, Capien MA, Burnett DA. Ezetimibe (SCH58235) localizes to the brush border of small intestinal enterocyte and inhibits enterocyte cholesterol uptake and absorption.Eur Heart J. 2000;21(suppl):636. Abstract.Google Scholar
  37. 37.
    Hernandez M, Montenegro J, Steiner M, et al. Intestinal absorption of cholesterol is mediated by a saturable, inhibitable transporter.Biochim Biophys Acta. 2000;1486:232–242.PubMedGoogle Scholar
  38. 38.
    Detmers PA, Patel S, Hernandez M, et al. A target for cholesterol absorption inhibitors in the enterocyte brush border membrane.Biochim Biophys Acta. 2000;20:243–252.Google Scholar
  39. 39.
    Brown WV. Novel approaches to lipid lowering: what is on the horizon?Am J Cardiol. 2001; 87(suppl 1):23B-27B.PubMedGoogle Scholar
  40. 40.
    Lipka LJ, LeBeaut AP, Veltri EP, Mellars LE, Bays HL, Moore PB. Reduction of LDL-cholesterol and elevation of HDL-cholesterol in subjects with primary hypercholesterolemia by SCH 58235: pooled analysis of two phase II studies.J Am Coll Cardiol. 2000;35(suppl A):257.Google Scholar
  41. 41.
    Knopp RH, Gitter H, Truitt T, et al. Ezetimibe reduces low-density lipoprotein cholesterol: results of a phase III, randomized, double-blind, placebo-controlled trial.Atherosclerosis Suppl. 2001;2:38.CrossRefGoogle Scholar
  42. 42.
    Kosoglou T, Seiberling M, Statkevich P, et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and atorvastatin.J Am Coll Cardiol. 2001; 37(suppl A):229A.Google Scholar
  43. 43.
    Olsson AG, Pears J, McKellar J, Mizan J, Raza A. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia.Am J Cardiol. 2001;88:504–508.PubMedCrossRefGoogle Scholar
  44. 44.
    Olsson A, Southworth H, Wilpshaar JW. Long-term efficacy and safety of rosuvastatin: results of a 52-week comparator-controlled trial versus atorvastatin.Eur Heart J. 2001;22(supp 1):253. Abstract.Google Scholar
  45. 45.
    Brown WV, Zedler BK, Bays HE, Hassman HA, Chitra RR. Long-term efficacy and safety of rosuvastatin: results of a 52-week comparator-controlled trial versus pravastatin and simvastatin.Eur Heart J. 2001;22(suppl):270. Abstract.Google Scholar
  46. 46.
    Davidson MH, Dillon MA, Gordon B, et al. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects.Arch Intern Med. 1999;159:1893–1900.PubMedCrossRefGoogle Scholar
  47. 47.
    Davidson MH, Toth P, Weiss S, et al. Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia.Clin Cardiol. 2001;24:467–474.PubMedGoogle Scholar
  48. 48.
    Davidson MH, Dicklin MR, Maki KC, Kleinpell RM. Colesevelam hydrochloride: a non-absorbed, polymeric cholesterol lowering agent.Expert Opin Invest Drugs. 2000;9:2663–2671.CrossRefGoogle Scholar
  49. 49.
    Knapp HH, Schrott H, Ma P, et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia.Am J Med. 2001;110:352–360.PubMedCrossRefGoogle Scholar
  50. 50.
    Goldberg A, Alagona P Jr, Capuzzi DM, et al. Multiple-dose efficacy and safety of an extendedrelease form of niacin in the management of hyperlipidemia.Am J Cardiol. 2000;85:1100–1105.PubMedCrossRefGoogle Scholar
  51. 51.
    Knopp RH, Alagona P, Davidson M, et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.Metabolism. 1998;47:1097–1104.PubMedCrossRefGoogle Scholar
  52. 52.
    Capuzzi DM, Guyton JR, Morgan JM, et al. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study.Am J Cardiol. 1998;82:74U-81U.PubMedCrossRefGoogle Scholar
  53. 53.
    Wolfe ML, Vartanian SF, Ross JL, et al. Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia.Am J Cardiol. 2001;87:476–479.PubMedCrossRefGoogle Scholar
  54. 54.
    Tavintharan S, Kashyap ML. The benefits of niacin in atherosclerosis.Curr Atheroscler Rep. 2001; 3:74–82.PubMedCrossRefGoogle Scholar
  55. 55.
    Kashyap ML, Evans R, Simmons PD, Kohler RM, McGovern ME. New combination niacin/ statin formulation shows pronounced effects on major lipoproteins and is well tolerated.J Am Coll Cardiol. 2000;35(suppl A):326.Google Scholar
  56. 56.
    Insull W, Koren M, Davignon J, et al. Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia.Atherosclerosis. 2001;157:137–144.PubMedCrossRefGoogle Scholar

Copyright information

© Health Communications Inc 2002

Authors and Affiliations

  • Benjamin Ansell
    • 1
  1. 1.Cardiovascular Disease PreventionUCLA Center for Primary Care-BasedLos AngelesUSA

Personalised recommendations